TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: 131 I-MIBG in Treating Patients With Refractory or Relapsed Neuroblastoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Original diagnosis of neuroblastoma based on 1 of the following criteria:~  * Histopathology~ * Elevated urine catecholamines with typical tumor cells in the bone marrow~* Refractory or relapsed disease, meeting 1 of the following criteria:~  * Failure to respond to standard therapy (e.g., combination chemotherapy with or without radiotherapy and surgery)~ * Evidence of disease progression (i.e., any new lesion or an increase in size of \> 25% of a pre-existing lesion) at any time~* Evaluable disease by MIBG scan within 6 weeks of study entry~PATIENT CHARACTERISTICS:~* Not pregnant or nursing~* Fertile patients must use effective contraception~* Negative pregnancy test~* Bilirubin \< 2 times normal~* AST/ALT ≤ 10 times normal~* Creatinine ≤ 2 mg/dL~* Absolute neutrophil count\* ≥ 750/mm\^3 (transfusion independent)~* Platelet count\* ≥ 50,000/mm\^3 (20,000/mm\^3 if stem cells are available and platelet transfusion independent)~* Hemoglobin\* ≥ 10 g/dL (transfusion allowed)~* No dyspnea at rest~* No exercise intolerance~* No oxygen requirement~* No clinically significant cardiac dysfunction~* No disease of any major organ system that would preclude study compliance~* No active infection that meets grade 3 or 4 toxicity criteria NOTE: \*Patients with granulocytopenia and/or thrombocytopenia due to tumor metastases to the bone marrow may be eligible at the discretion of the principal investigator~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* Recovered from prior therapy~* At least 2 weeks since prior antitumor therapy~* At least 3 months since prior radiotherapy to any of the following fields:~  * Craniospinal~ * Total abdominal~ * Whole lung~ * Total body~* At least 1 day since prior cytokine therapy (e.g., filgrastim \[G-CSF\], sargramostim \[GM-CSF\], interleukin-6, or epoetin alfa)~* Prior iodine I 131 metaiodobenzylguanidine allowed provided it was given more than 6 months ago AND patient has adequate hematopoietic stem cells available~* No concurrent hemodialysis

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Multicenter Trial to Treat Patients With Relapsed/Refractory Aggressive Non Hodgkin Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent~* Histologically confirmed aggressive lymphomas,~* Patient requires treatment because NHL relapses~* Measurable disease~* Recovery from any non-hematological toxicity derived from previous treatments. The presence of alopecia and NCI-CTC grade \< 2 symptomatic peripheral neuropathy is allowed.~* Age \> 18 years.~* Performance status (ECOG) \< 2~* Adequate renal, hepatic, and bone marrow function (assessed \< 14 days before inclusion in the study)~* Left ventricular ejection fraction within normal limits.~Exclusion Criteria:~* Prior therapy with Aplidin®.~* Concomitant therapy with any anti-lymphoproliferative agent~* Acute lymphoblastic leukemia.~* CNS lymphoma.~* HIV-associated lymphoma.~* Prior gene therapy with viral vectors.~* More than three previous lines of systemic biological agents or chemotherapies. Wash-out periods since the end of the precedent therapy less than:~  * 6 weeks for nitroso-urea or high dose chemotherapy~ * 3 weeks for other chemotherapies or biological agents~ * 4 weeks for radiation or radionuclide therapy (6 weeks in case of prior extensive external beam radiation (more than 25% of bone marrow distribution).~ * 4 weeks for major prior surgery~ * 30 days for any investigational product~ * 4 weeks for immunosuppressive therapy after allogeneic hematopoietic stem cell transplantation.~* Pregnant or lactating women.~* Men and women of reproductive potential who are not using effective contraceptive methods~* History of another neoplastic disease. Exceptions: Non-melanoma skin cancer,cCarcinoma in situ of any site,any other cancer curatively treated and no evidence of disease for at least 10 years.~* Known cerebral or leptomeningeal involvement.~* Other relevant diseases or adverse clinical conditions~* Treatment with any investigational product in the 30 days period before inclusion in the study.~* Known hypersensitivity to Aplidin®, mannitol, cremophor EL, or ethanol~* Limitation of the patient's ability to comply with the treatment or follow-up protocol.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm One (Type: EXPERIMENTAL): Aplidin® given as a 1-hour weekly IV infusion

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Small Particle Steroids in Refractory Asthma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18-80~* ACQ \>1.5 or a requirement for oral steroids twice a year or more~* High dose inhaled steroid (\>1000mcg BDP or equivalent)~* Treatment with or unsuccessful trial of:~  * long-acting beta agonist~ * leukotriene antagonist~* Sputum eosinophil count \>3% despite high dose inhaled steroid or \>2% with serum eosinophils \>0.4x10exp9/l~* Clinical response to 2 weeks of oral prednisolone: (any one)~  * reduction in ACQ by 0.5 or more~ * increase in FEV1 by 200ml~ * normalisation of exhaled nitric oxide or reduction of \>25ppb~Exclusion Criteria:~* Current smoker, or ex-smoker for \<12 months~* Current treatment with an extrafine steroid inhaler~* Respiratory infection within the last 4 weeks~* Pregnancy or lactation~* Poor compliance with usual asthma medication~* Clinical diagnosis of significant bronchiectasis~* Use of a medication which may interact with ciclesonide:~  * ketoconazole or itraconazole~ * ritonavir, nelfinavir

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Ciclesonide (Type: ACTIVE_COMPARATOR): Ciclesonide 320 microgrammes twice daily
- Placebo (Type: PLACEBO_COMPARATOR): Placebo 2 inhalations twice daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Mineralocorticoid Receptor, NMDA Receptor and Cognitive Function in Depression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18-65 years~* Depressed male and female patients according to DSM-V \& minimum of 17-items Hamilton Depression Score of 18~* healthy controls~* informed consent signed~Exclusion Criteria:~* Current use of antidepressants, antipsychotics, or mood stabilizer~* Relevant medical or neurological disorders~* Pregnancy or unsure contraception~* Relevant psychiatric comorbidity (bipolar or psychotic disorders)~* Active alcohol or other substance abuse/dependance

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Placebo+Placebo (Type: PLACEBO_COMPARATOR): Placebo: pill, 8mm, single dose, Lichtenstein, Winthrop Arzneimittel GmbH.
- Fludrocortisone+Placebo (Type: ACTIVE_COMPARATOR): Fludrocortisone: pill, Astonin H 0,1gm, single dose, Merck Serono GmbH~Placebo: pill, 8mm, single dose, Lichtenstein, Winthrop Arzneimittel GmbH.
- Placebo+D-Cycloserine (Type: ACTIVE_COMPARATOR): Placebo: pill, 8mm, single dose, Lichtenstein, Winthrop Arzneimittel GmbH.~D-Cycloserine: capsule, Cycloserine 250mg, single dose, King Pharmaceuticals Ltd
- Fludrocortison+D-Cycloserine (Type: ACTIVE_COMPARATOR): Fludrocortisone: pill, Astonin H 0,1gm, single dose, Merck Serono GmbH~D-Cycloserine: capsule, Cycloserine 250mg, single dose, King Pharmaceuticals Ltd

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Chinese Herbal Medicine to Prevent and Treat COVID-19 Close Contacts

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Household contact exposure to individuals with SARS-CoV-2 infection~2. Aged ≥18~3. General healthy or have a chronic, stable medical condition~4. Voluntarily signing a written informed consent form~5. Able to follow written and oral instructions in Chinese~Exclusion Criteria:~1. Moderate to severe symptomatic SARS-CoV-2 infection~2. An allergic history to Chinese herbal drugs or a known allergy to the ingredients of the study drug~3. Pregnancy, breastfeeding or plan to become pregnant within the study timeframe~4. Vulnerable adults (i.e., mentally or physically disabled to take care of himself/herself)~5. Any physical examination findings, and/or history of any illness, or concomitant medications that, in the opinion of the study investigator, might not be suitable to participate in the study

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Treatment group (Type: EXPERIMENTAL): Chinese Herbal Medicine
- Control group (Type: NO_INTERVENTION): usual care

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Patients With Metastatic and/or Advanced Renal Cell Carcinoma, Treated With Sunitinib/Axitinib.

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria~1. Over the age of 18 years~2. Diagnosis of renal cell carcinoma~3. Treatment with sunitinib and/or axitinib~4. Timeframe: from database inception date (2002) until June 30, 2018.~Exclusion criteria~Patients meeting any of the following criteria will not be included in the study:~1. Under the age of 18 years~2. Diagnosis other than renal cell carcinoma~3. No treatment with sunitinib and/or axitinib

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patients with advanced RCC (Type: None): Patients with a diagnosis of kidney cancer (renal cell carcinoma, advanced or metastatic)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Observe the Effectiveness of Empagliflozin, Other SGLT-2 Inhibitors, or DPP-4 Inhibitors in Patients With Type 2 Diabetes

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Dispensation or any other record of empagliflozin, any SGLT-2 inhibitor, or any DPP-4 inhibitor use during the study period~* No dispensation or any other record of any other SGLT-2 inhibitor or DPP-4 inhibitor use during the preceding 12 months including at index date~* Having a diagnosis of T2DM before the index date, based on ICD-10 codes or other available data~Exclusion Criteria:~* Aged \<18 years on the first dispensation date or date of the first record of empagliflozin, any SGLT-2 inhibitor or any DPP-4 inhibitor use~* Type 1 diabetes mellitus~* Secondary diabetes~* Gestational diabetes~* Having a diagnosis of ESRD during the 12 months before the index date~* \<12 months of available data before the index date, and/or no complete history of drug dispensations/other records of the drug use during this period~* Missing or ambiguous data on age or sex

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- New users of SGLT-2i (Type: None): Patients with type 2 diabetes mellitus (T2DM), who were new users of any sodium-glucose cotransporter-2 inhibitors (SGLT-2i) including empagliflozin.
- New users of DPP-4i (Type: None): Patients with type 2 diabetes mellitus (T2DM), who were new users of dipeptidyl peptidase-4 inhibitors (DPP-4i).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Clinical Study to Evaluate Experimental Children's Toothpastes in an In-Situ Caries Model

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy males and females aged 11 to 14 inclusive who have an unstimulated salivary flow rate of at least 0.2 mL/minute and a stimulated salivary flow rate of at least 0.8 mL/minute (Screening Visit 1).~Exclusion Criteria:~-

- Gender: ALL
- Minimum Age: 11 Years
- Maximum Age: 14 Years
- Healthy Volunteers: t

Study Arms:
- Fluoride free toothpaste (Type: PLACEBO_COMPARATOR): toothpaste with no fluoride
- 1426ppm Fluoride Toothpaste (Type: EXPERIMENTAL): Experimental toothpaste containing 1426 ppm Fluoride
- 1000 ppm Fluoride Toothpaste (Type: EXPERIMENTAL): Experimental toothpaste containing 1000 ppm Fluoride
- 500 ppm Toothpaste (Type: EXPERIMENTAL): Experimental toothpaste containing 500 ppm Fluoride

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Lurasidone HCl A Phase 3 Study of Patients With Acute Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Provide written informed consent and aged between 18 and 75 years of age.~* Meets DSM-IV criteria for a primary diagnosis of schizophrenia.~* Not pregnant, if of reproductive potential agrees to remain abstinent or use adequate and reliable contraception for duration of study.~* Able and agrees to remain off prior antipsychotic medication for the duration of study.~* Good physical health on the basis of medical history, physical examination, and laboratory screening.~* Willing and able to comply with the protocol, including the inpatient requirements and outpatient visits.~Exclusion Criteria:~* Considered by the investigator to be at imminent risk of suicide or injury to self, others or property.~* Any chronic organic disease of the CNS (other than schizophrenia).~* Used investigational compound within 30 days.~* Clinically significant or history of alcohol abuse/alcoholism or drug abuse/dependence within the last 6 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Lurasdione 40mg tablets (Type: EXPERIMENTAL): None
- 120mg (Type: EXPERIMENTAL): None
- 15mg Olz (Type: ACTIVE_COMPARATOR): None
- Sugar pill (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Efficacy of Novel Ibuprofen Acetaminophen Combination Formulations in the Treatment of Post-surgical Dental Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Males and females 16 to 40 years of age~* Moderate to severe post-operative pain following surgical extraction of three or more third molar teeth~Exclusion Criteria:~* Presence of history of significant hepatic, renal, endocrine, cardiovascular, neurological, psychiatric, gastrointestinal, pulmonary, hematologic or metabolic disorder~* Pregnant or breastfeeding females

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- Ibuprofen/acetaminophen (lower dose) (Type: EXPERIMENTAL): None
- Ibuprofen/acetaminophen (middle dose) (Type: EXPERIMENTAL): None
- Ibuprofen/acetaminophen (high dose) (Type: EXPERIMENTAL): None
- Ibuprofen (Type: ACTIVE_COMPARATOR): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Oxytocin Treatment of Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Meeting DSM-IV criteria for paranoid or undifferentiated schizophrenia for at least 1 year.~* Scoring \> or equal to 4 on the suspiciousness/persecution (paranoia) subscale of the Positive and Negative Symptoms Scale (PANSS), a full PANSS score \> or equal to 60: stability of symptom severity and on the same medication(s) and dose(s) for at least 1 month; low to moderate depressive symptoms.~Exclusion Criteria:~* Low literacy as indicated by an inability to read and understand the consent form.~* Dependence on substances other than tobacco or caffeine.~* Positive urine drug screen for illegal substances or drugs that have not been prescribed.~* Debilitating medical conditions (including AIDS; HIV infection alone will not be grounds for exclusion).~* Major surgery or trauma in the past year will be grounds for exclusion although subjects determined to be recovered and stable may be included at the discretion of the PI.~* Pregnancy, breast-feeding.~* Having given birth in the past 6 months or breast-feeding in the past 3 months.~* Individuals judged unable to learn self-administration of intranasal treatments and/or not sufficiently reliable to do so will be excluded.~* Abnormalities found during medical evaluation will be grounds for exclusion although subjects with laboratory measures barely outside the normal range may be included at the discretion of the Principal Investigator.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- intranasal spray with oxytocin (Type: EXPERIMENTAL): Twice daily intranasal oxytocin spray (24 IU, 6 insufflations/dose) for 6 weeks
- intranasal spray without oxytocin (Type: PLACEBO_COMPARATOR): Twice daily intranasal spray without oxytocin (six 0.1 ml insufflations/dose) for 6 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Introduction of an Oral Live Human Rotavirus (Rotarix) Vaccine in Matlab

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* A male or female infant at least 6 weeks of age and not older than 20 weeks of age at the time of first dose of Rotarix.~* An infant whose parent or guardian's primary residence, at the time of first EPI vaccinations, is a village selected to receive Rotarix.~* Written informed consent obtained from the parent or guardian of the subject, prior to the subject's first study vaccination~Exclusion Criteria:~* Hypersensitivity to the active substance or any component in the vaccine~* Hypersensitivity after previous administration of rotavirus vaccines.~* Previous history of intussusception.~* Subjects with uncorrected congenital malformation of the gastrointestinal tract that would predispose for intussusception.~* Infants with known or suspected immunodeficiency.~* Administration of Rotarix should be postponed in subjects suffering from an acute severe febrile illness only if that illness also results in postponement of other EPI vaccinations.

- Gender: ALL
- Minimum Age: 6 Weeks
- Maximum Age: 20 Weeks
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): All eligible children in the experimental arm will be vaccinated with the Rotavirus vaccine
- 2 (Type: NO_INTERVENTION): Children will not be vaccinated with rotavirus vaccine.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Individualizing Dual Antiplatelet Therapy After Percutaneous Coronary Intervention - The IDEAL-PCI Registry

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* all consecutive PCI patients with stent implantation of our institution~Exclusion Criteria:~* pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- standard therapy (Type: ACTIVE_COMPARATOR): standard dual antiplatelet therapy after PCI for all patient populations (stable CVD and ACS)
- individualized therapy (Type: EXPERIMENTAL): dual antiplatelet therapy modified according to clopidogrel on-treatment platelet reactivity measured by Multiplate Analyzer

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete